BRPI0411868B8 - derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase - Google Patents

derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase

Info

Publication number
BRPI0411868B8
BRPI0411868B8 BRPI0411868A BRPI0411868A BRPI0411868B8 BR PI0411868 B8 BRPI0411868 B8 BR PI0411868B8 BR PI0411868 A BRPI0411868 A BR PI0411868A BR PI0411868 A BRPI0411868 A BR PI0411868A BR PI0411868 B8 BRPI0411868 B8 BR PI0411868B8
Authority
BR
Brazil
Prior art keywords
pyrrole
pyrazole derivatives
kinase inhibitors
derivatives active
active
Prior art date
Application number
BRPI0411868A
Other languages
English (en)
Inventor
Forte Barbara
Fancelli Daniele
Moll Jurgen
Varasi Mario
Vianello Paola
Original Assignee
Nerviano Medical Science S R L
Pfizer Italia Srl
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Science S R L, Pfizer Italia Srl, Pharmacia Italia Spa filed Critical Nerviano Medical Science S R L
Publication of BRPI0411868A publication Critical patent/BRPI0411868A/pt
Publication of BRPI0411868B1 publication Critical patent/BRPI0411868B1/pt
Publication of BRPI0411868B8 publication Critical patent/BRPI0411868B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

"derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase. a presente invenção refere-se a derivados de pirrol[3,4-c]pirazol de fórmula i e seus sais farmaceuticamente aceitáveis, como definido no relatório descritivo, processo para sua preparação e composições farmacêuticas compreendendo-os; os compostos da invenção podem ser úteis em terapia no tratamento de doenças associadas com uma atividade de proteína cinase desregulada, como câncer.
BRPI0411868A 2003-07-09 2004-07-08 derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase BRPI0411868B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48581403P 2003-07-09 2003-07-09
PCT/EP2004/007515 WO2005005427A1 (en) 2003-07-09 2004-07-08 PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS

Publications (3)

Publication Number Publication Date
BRPI0411868A BRPI0411868A (pt) 2006-08-08
BRPI0411868B1 BRPI0411868B1 (pt) 2019-11-12
BRPI0411868B8 true BRPI0411868B8 (pt) 2021-05-25

Family

ID=34062099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411868A BRPI0411868B8 (pt) 2003-07-09 2004-07-08 derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase

Country Status (42)

Country Link
US (2) US7141568B2 (pt)
EP (1) EP1644376B1 (pt)
JP (1) JP4728232B2 (pt)
KR (1) KR101075711B1 (pt)
CN (1) CN100564380C (pt)
AP (1) AP2214A (pt)
AR (1) AR050045A1 (pt)
AT (1) ATE480540T1 (pt)
AU (1) AU2004255347B2 (pt)
BR (1) BRPI0411868B8 (pt)
CA (1) CA2531759C (pt)
CR (1) CR8171A (pt)
CY (1) CY1110832T1 (pt)
DE (1) DE602004029045D1 (pt)
DK (1) DK1644376T3 (pt)
DO (1) DOP2004000949A (pt)
EA (1) EA009462B1 (pt)
EC (1) ECSP056246A (pt)
ES (1) ES2349780T3 (pt)
GE (1) GEP20084395B (pt)
GT (2) GT200400133AA (pt)
HK (1) HK1089769A1 (pt)
HN (1) HN2004000232A (pt)
IL (1) IL172923A (pt)
IS (1) IS2843B (pt)
MA (1) MA28064A1 (pt)
ME (1) MEP51908A (pt)
MX (1) MXPA06000362A (pt)
MY (1) MY139072A (pt)
NO (1) NO332361B1 (pt)
NZ (1) NZ544514A (pt)
PA (1) PA8606201A1 (pt)
PE (1) PE20050325A1 (pt)
PL (1) PL1644376T3 (pt)
PT (1) PT1644376E (pt)
RS (2) RS52155B (pt)
SI (1) SI1644376T1 (pt)
TN (1) TNSN06009A1 (pt)
TW (1) TWI343382B (pt)
UA (1) UA81682C2 (pt)
WO (1) WO2005005427A1 (pt)
ZA (1) ZA200600095B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229824B1 (en) * 2000-08-10 2014-08-28 Pfizer Italia Srl Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0518509A2 (pt) * 2005-01-10 2008-11-25 Pfizer pirrolopirazàis, inibidores de cinase potentes
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200808311A (en) 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
WO2008052931A1 (en) * 2006-11-03 2008-05-08 Nerviano Medical Sciences S.R.L. A method of administering an antitumor compound
AR071780A1 (es) * 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
US20110129467A1 (en) * 2008-07-24 2011-06-02 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
JP5518062B2 (ja) * 2008-07-24 2014-06-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ オーロラキナーゼ阻害剤および抗悪性腫瘍剤を含む治療用組み合わせ
US20100022553A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
US20100183601A1 (en) 2008-12-22 2010-07-22 Millennium Pharmaceuticals, Inc. Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies
EA025352B1 (ru) 2011-12-12 2016-12-30 Др. Редди'С Лабораториз Лтд. ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ТРОПОМИОЗИН-РЕЦЕПТОРНОЙ КИНАЗЫ (Trk)
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 （R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
US9394305B2 (en) 2014-06-23 2016-07-19 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors
CN107735401B (zh) 2015-06-15 2021-08-31 宇部兴产株式会社 取代二氢吡咯并吡唑衍生物
CN107337674B (zh) * 2016-04-29 2019-09-20 江苏吉贝尔药业股份有限公司 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717380B1 (fr) * 1994-03-15 1996-04-26 Oreal Compositions cosmétiques contenant un mélange synergétique de polymères conditionneurs.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19932144A1 (de) * 1999-07-09 2001-01-11 Basf Ag Mikrokapselzubereitungen und Mikrokapseln enthaltende Wasch- und Reinigungsmittel
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EA005373B1 (ru) 1999-08-12 2005-02-24 Фармация Италия С.П.А. Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств
HU229824B1 (en) 2000-08-10 2014-08-28 Pfizer Italia Srl Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
US20040019046A1 (en) 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
JP2004519486A (ja) 2001-01-26 2004-07-02 フアルマシア・イタリア・エツセ・ピー・アー クロマン誘導体、その製造方法及びその抗腫瘍剤としての使用
JP4542338B2 (ja) 2001-09-26 2010-09-15 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害因子として活性なアミノインダゾール誘導体、それらの製造方法及びそれらを含有する医薬組成物
MXPA05000947A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Also Published As

Publication number Publication date
CA2531759C (en) 2013-04-02
EA009462B1 (ru) 2007-12-28
US7141568B2 (en) 2006-11-28
DK1644376T3 (da) 2011-01-03
RS52155B (en) 2012-08-31
MXPA06000362A (es) 2006-03-28
ZA200600095B (en) 2007-01-31
NO332361B1 (no) 2012-09-03
JP4728232B2 (ja) 2011-07-20
BRPI0411868B1 (pt) 2019-11-12
IL172923A0 (en) 2006-06-11
AU2004255347B2 (en) 2010-04-08
MY139072A (en) 2009-08-28
GT200400133A (es) 2005-04-18
ATE480540T1 (de) 2010-09-15
GT200400133AA (es) 2007-07-10
UA81682C2 (en) 2008-01-25
IL172923A (en) 2011-09-27
PL1644376T3 (pl) 2011-03-31
US20060276471A1 (en) 2006-12-07
TWI343382B (en) 2011-06-11
SI1644376T1 (sl) 2010-11-30
PT1644376E (pt) 2010-09-24
PA8606201A1 (es) 2005-08-04
CN100564380C (zh) 2009-12-02
EA200600209A1 (ru) 2006-06-30
EP1644376B1 (en) 2010-09-08
NZ544514A (en) 2009-07-31
HN2004000232A (es) 2011-01-17
CA2531759A1 (en) 2005-01-20
GEP20084395B (en) 2008-06-10
NO20060113L (no) 2006-04-05
RS20060004A (en) 2008-06-05
ES2349780T3 (es) 2011-01-11
AR050045A1 (es) 2006-09-27
US20050032839A1 (en) 2005-02-10
EP1644376A1 (en) 2006-04-12
DE602004029045D1 (de) 2010-10-21
HK1089769A1 (en) 2006-12-08
IS2843B (is) 2013-08-15
AP2214A (en) 2011-03-04
JP2009513525A (ja) 2009-04-02
CY1110832T1 (el) 2015-06-10
ECSP056246A (es) 2006-04-19
AP2006003480A0 (en) 2006-02-28
KR101075711B1 (ko) 2011-10-21
CN1820009A (zh) 2006-08-16
DOP2004000949A (es) 2005-01-15
IS8192A (is) 2005-12-22
KR20060033001A (ko) 2006-04-18
MA28064A1 (fr) 2006-08-01
BRPI0411868A (pt) 2006-08-08
TNSN06009A1 (fr) 2007-10-03
TW200510385A (en) 2005-03-16
US7582628B2 (en) 2009-09-01
WO2005005427A1 (en) 2005-01-20
CR8171A (es) 2006-08-09
PE20050325A1 (es) 2005-05-17
AU2004255347A1 (en) 2005-01-20
MEP51908A (en) 2011-05-10

Similar Documents

Publication Publication Date Title
BRPI0411868B8 (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BRPI0507375A (pt) derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase
BR0315988A (pt) Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MY143206A (en) 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors
BRPI0108394B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
HK1157337A1 (pt)
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
BRPI0508706A (pt) derivados de dicloro-fenil-pirido[2,3-d]pirimidina inusitados, sua fabricação e uso como agentes farmacêuticos
BRPI0016329B8 (pt) bis-indolilmaleimidas substituídas para inibição de proliferação de células, seu processo de preparação e seu uso, bem como composição farmacêutica.
BR112023025042A2 (pt) Pirrol[2,3-d]pirimidinas substituídas, preparação das mesmas e aplicação terapêutica das mesmas
CU23566B7 (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa
UY28409A1 (es) Derivados de pirrolo (3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparación y composiciones farmaceuticas que los comprenden
TW200508236A (en) Pyrazolo[1,5-a]pyrimidine derivatives

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: PHARMACIA ITALIA S.P.A. (IT)

Free format text: A FIM DE ATENDER AS TRANSFERENCIAS REQUERIDAS ATRAVES DA PETICAO NO 020110122065/RJ DE 29/11/2011, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO RELATIVO A PRIMEIRA TRANSFERENCIA DEVIDAMENTE NOTARIZADO.

B25A Requested transfer of rights approved

Owner name: PFIZER ITALIA S.R.L. (IT)

B25A Requested transfer of rights approved

Owner name: NERVIANO MEDICAL SCIENCE S.R.L. (IT)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2678 DE 03-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.